| Title |
The FDA’s latest move to expand eligibility for oncology trials — a double-edged sword?
|
|---|---|
| Published in |
Nature Reviews Clinical Oncology, September 2021
|
| DOI | 10.1038/s41571-021-00559-0 |
| Pubmed ID | |
| Authors |
Mark P. Lythgoe, Vinay Prasad |
X Demographics
The data shown below were collected from the profiles of 18 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 17% |
| United Kingdom | 2 | 11% |
| Switzerland | 1 | 6% |
| China | 1 | 6% |
| Unknown | 11 | 61% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 13 | 72% |
| Scientists | 2 | 11% |
| Practitioners (doctors, other healthcare professionals) | 2 | 11% |
| Science communicators (journalists, bloggers, editors) | 1 | 6% |
Mendeley readers
The data shown below were compiled from readership statistics for 4 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 4 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 1 | 25% |
| Lecturer | 1 | 25% |
| Student > Master | 1 | 25% |
| Unknown | 1 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 2 | 50% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 25% |
| Unknown | 1 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 June 2022.
All research outputs
#3,377,893
of 25,571,620 outputs
Outputs from Nature Reviews Clinical Oncology
#795
of 2,352 outputs
Outputs of similar age
#74,222
of 436,606 outputs
Outputs of similar age from Nature Reviews Clinical Oncology
#13
of 30 outputs
Altmetric has tracked 25,571,620 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,352 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 19.9. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 436,606 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.